Stockreport

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Omega Therapeutics, Inc.  (OMGA) 
PDF Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration [Read more]